DrugPatentWatch Database Preview

INREBIC Drug Profile

« Back to Dashboard

Which patents cover Inrebic, and when can generic versions of Inrebic launch?

Inrebic is a drug marketed by Impact and is included in one NDA. There are four patents protecting this drug.

This drug has seventy-six patent family members in thirty-three countries.

The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this compound. Additional details are available on the fedratinib hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Inrebic

Inrebic will be eligible for patent challenges on August 16, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 29, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for INREBIC

International Patents:	76
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	78
Patent Applications:	57
Drug Prices:	Drug price information for INREBIC
DailyMed Link:	INREBIC at DailyMed

See drug prices for INREBIC

Generic Entry Opportunity Date for INREBIC

NDA:

212327

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for INREBIC

091D268

2TA

3-methyl-5-(2-morpholinoethyl)-6,7-dehydro-1H-pyrrolo[3,2-c]pyridine-4(5H)-one

6L1XP550I6

936091-26-8

936091-26-8 pound not TG101348 pound not TG 101348

945381-69-1

A25534

AB1008513

ABP000705

AC-30260

AK-50248

AKOS015842621

AN-4247

AOB2041

AS-16248

BC644857

BCP02300

BDBM50332294

Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-

BRD-K12502280-001-01-5

C27H36N6O3S

cc-67

CHEBI:91408

CHEMBL1287853

CS-0052

D10630

DA-40258

DA-45538

DB12500

DTXSID90239483

EX-5961

EX-A170

Fedratinib

Fedratinib (SAR302503, TG101348)

Fedratinib (USAN/INN)

Fedratinib [USAN:INN]

Fedratinib TG101348

Fedratinib-SAR302503-TG101348

Fedratinib|||N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-benzenesulfonamide

FT-0705969

FT-0763396

FT-0766818

GTPL5716

HMS3656L19

HMS3744G17

HY-10409

J-523769

KIN0000251

MFCD12922515

MLS006011155

N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyr

n-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino

N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide

N-(tert-butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide

N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide

N-Tert-butyl-3-(5-methyl-2-(4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino)-pyrimidin-4-ylamino)-benzenesulfonamide

N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide

N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide

N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide

NCGC00244252-01

NCGC00244252-07

RS0112

s2736

SAR 302503

SAR-302503

SAR302503

SAR302503 (TG-101348)

SB14604

SC-86405

SCHEMBL263741

SMR004702929

SW218187-2

SYN1104

TG 101348

Tg-101348

TG101348

TG101348 (SAR302503)

TG101348 HCl

TG101348(Fedratinib)

TG101348/TG-101348/

UNII-6L1XP550I6

W-5547

Y0268

ZINC19862646

US Patents and Regulatory Information for INREBIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impact	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes			Y
Impact	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes				Y
Impact	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes
Impact	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes				Y
Impact	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes
Impact	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes

International Patents for INREBIC

Country	Patent Number	Estimated Expiration
Norway	20082447
Ukraine	109412
Portugal	1951684
Ukraine	114076
New Zealand	592990
Canada	2816710